Drug news
Astra Zeneca acquires global rights to SGN 001 for Respiratory Tract Viral Infections - Synairgen PLC
Synairgen plc announced a global licence agreement with AstraZeneca for SNG 001, a novel, inhaled interferon beta (IFN-beta) in clinical development for treating Respiratory Tract Viral Infections in patients with severe Asthma. SNG 001 supports the immune system by correcting a deficiency which makes patients vulnerable to respiratory tract viral infections.
In early 2015, AstraZeneca will commence a Phase IIa study in patients with severe Asthma.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.